IsoRay

IsoRay Current Liabilities

Delisted

The Current Liabilities of IsoRay (ISR) as of Nov 4, 2026 is 3.57 M USD. In the previous year, Current Liabilities was 2.87 M USD — a change of 24.16% (higher).

Current Liabilities

3.57 MUSD

YoY

24.16%

Last updated:

Current Liabilities of IsoRay is 2022 3.57 M USD. Current Liabilities of IsoRay was 2021 2.87 M USD. It decreases by 24.16% higher compared to the previous year.

The IsoRay Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2015
1.65 M USD
Jan 1, 2016
1.50 M USD
Jan 1, 2017
1.44 M USD
Jan 1, 2018
2.12 M USD
Jan 1, 2019
1.56 M USD
Jan 1, 2020
2.50 M USD
Jan 1, 2021
2.87 M USD
Jan 1, 2022
3.57 M USD
The IsoRay Current Liabilities history
YEARCurrent LiabilitiesYoY
3.57 MUSD+24.16%
2.87 MUSD+15.06%
2.50 MUSD+60.10%
1.56 MUSD-26.60%
2.12 MUSD+47.09%
1.44 MUSD-3.98%
1.50 MUSD-9.10%
1.65 MUSD-20.11%
2.07 MUSD+83.33%
1.13 MUSD-25.00%
1.51 MUSD-2.60%
1.55 MUSD-23.64%
2.02 MUSD-3.48%
2.10 MUSD+29.02%
1.63 MUSD-53.30%
3.48 MUSD+8.12%
3.22 MUSD-84.92%
21.36 MUSD+5,338.84%
392,639.00USD-30.52%
565,128.00USD-47.86%
1.08 MUSD+70.97%
634,000.00USD-28.20%
883,000.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IsoRay Stock analysis

What does IsoRay do? The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IsoRay stock

Current Liabilities of IsoRay is 3.57 M USD in 2022.

Current Liabilities of IsoRay changed from 2.87 M USD to 3.57 M USD, representing a 24.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities IsoRay since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's IsoRay historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IsoRay

All Key Metrics — IsoRay